Table 5. . Treatment of recurrent anaplastic astrocytoma.
| Study (year) | Trial | # | Outcome | Ref. | ||
|---|---|---|---|---|---|---|
| Response (%) | PFS-6 (%) | mOS (weeks) | ||||
| Wong (1999) | Composite | 150 | 14 | 31 | 47 | [80] |
| Yung (1999) | TMZ | 162 | 35 | 44 | 54 | [81] |
| Brem (1995) | Gliadel | 28 | NS | 64 | 31 | [82] |
| Yung (1996) | cRA | 28 | 11 | NS | 34 | [83] |
| Jaeckle (2003) | cRA+TMZ | 28 | 15 | 46 | 47 | [84] |
| Levin (1992) | DFMO | 44 | 9 | NS | 62 | [85] |
| Levin (1992) | TPCH | 38 | 34 | NS | 50 | [86] |
| Chamberlain (1999) | Taxol | 24 | 13 | NS | 72 | [87] |
| Chamberlain (2007) | Cytoxan | 40 | 22.5 | 40 | 28 | [88] |
| Chamberlain(2008) | CPT-11 | 40 | 23 | 40 | 28 | [89,90,91] |
| Vredenbergh(2007) | CPT-11+Avastin | 9 | 67 | 56 | NS | [92] |
CPT-11: Irinotecan; cRA: Cis-retinoic acid; DFMO: Difluoromethyl ornithine; TMZ: Temozolomide; TPCH: 6-thioguanine, procarbazine, CCNU (lomustine), hydroxyurea.